Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) Director Matthew L. Posard sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now directly owns 109,755 shares […]
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) Director Matthew L. Posard sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now directly owns 109,755 shares […]
Scout Investments Inc. decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 261,483 shares of the biopharmaceutical company’s stock after selling 4,095 shares during the period. Scout Investments Inc. owned about 0.20% of Halozyme […]
TD Asset Management Inc Increases Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.
TD Asset Management Inc Increases Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.